Literature Scan: NSAIDs

Size: px
Start display at page:

Download "Literature Scan: NSAIDs"

Transcription

1 Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon Phone Fax Literature Scan: NSAIDs Date of Review: March 2016 Date of Last Review: November 2014 Current Status of PDL Class: See Appendix 1. Conclusions: Since the last NSAID scan, there is limited new comparative evidence from three Cochrane systematic reviews and two randomized controlled trials (RCTs). There is also one new FDA safety alert regarding cardiovascular risk with oral NSAIDs. There is low quality evidence that NSAIDs are more effective than placebo for treating chronic low back pain, with a mean difference in the pain intensity score using the 100 point visual analog scale (VAS) from baseline of 3.30 (95% CI 5.33 to 1.27). The clinical significance of this change remains unclear. There is high quality evidence of a significant reduction in pain with NSAIDs compared to placebo in the treatment of ankylosing spondylitis (AS). There is low quality evidence of no difference between specific NSAIDs for both the treatment of chronic low back pain and AS. Recommendations: No further review or research needed. Evaluate comparative drug costs in the executive session. Previous Conclusions/Conclusions: No further review or research needed. Evaluate comparative drug costs in the executive session. Methods: An OHSU Drug Effectiveness Review Project literature scan was used to identify randomized controlled trials (RCTs) and systematic reviews through November A Medline literature search for new systematic reviews and RCTs assessing clinically relevant outcomes to active controls, or placebo if needed, was conducted to present date. A summary of the clinical trials is available in Appendix 2 with abstracts presented in Appendix 3. The Medline search strategy used for this literature scan is available in Appendix 4, which includes dates, search terms and limits used. The OHSU Drug Effectiveness Review Project, Agency for Healthcare Research and Quality (AHRQ), Cochrane Collection, National Institute for Health and Clinical Excellence (NICE), Department of Veterans Affairs, BMJ Clinical Evidence, and the Canadian Agency for Drugs and Technologies in Health (CADTH) resources were manually searched for high quality and relevant systematic reviews. When necessary, systematic reviews are critically appraised for quality using the AMSTAR tool and clinical practice guidelines using the AGREE tool. The FDA website was searched for new drug approvals, indications, and pertinent safety alerts. Finally, the AHRQ National Guideline Clearinghouse (NGC) was searched for updated and recent evidence based guidelines.

2 The primary focus of the evidence is on high quality systematic reviews and evidence based guidelines. Randomized controlled trials will be emphasized if evidence is lacking or insufficient from those preferred sources. New Systematic Reviews: A recent Cochrane Systematic Review compared the efficacy and harms of NSAIDs compared with other oral analgesics for treating acute soft tissue injury. 1 Sixteen trials (n=2144) were included. The evidence was either low quality or very low quality with study limitations including suboptimal dosing of single comparators, imprecision, and indirectness. Nine studies compared NSADs with acetaminophen (APAP). There were no significant differences between the two groups in pain at any time point measured, swelling, and return to function. There was also low quality evidence of no difference in gastrointestinal adverse events (RR 1.76; 95% CI 0.99 to 3.14) between NSAIDs and APAP. Four studies compared opioids to NSAIDs. There was low quality evidence for a lack of clinically important differences between the groups for pain or swelling. No studies compared NSAIDs with complementary and alternative medicines and the review did not evaluate the comparative effectiveness of different NSAIDs or COX 2 inhibitors. 1 Another Cochrane Systematic Review evaluated the use of NSAIDs for chronic low back pain. 2 There was low quality evidence from six studies (n=1354) that NSAIDs are more effective than placebo, with a mean difference in pain intensity score from baseline of 3.30 mm (95% CI 5.33 to 1.27). The clinical significance of this is unclear as studies have suggested that a 13 mm difference on the visual analogue scale (VAS) is the minimum clinically significant difference. 3 In addition, patients with more severe pain require a greater change in the VAS to demonstrate clinically significant lessening of pain. There was also low quality evidence that NSAIDs are modestly more effective than placebo at reducing disability on a scale from 0 24 (mean difference from baseline 0.85; 95% CI 1.30 to 0.40) with a median follow up of 84 days. Although there was no significant difference in adverse events between the NSAID and placebo groups (RR 1.04; 95% CI 0.92 to 1.17), it is likely this is underestimated in trials due to the their short duration follow up. Comparative trials were limited and demonstrated no difference for ibuprofen versus diclofenac and piroxicam versus indomethacin. A third Cochrane Review compared oral NSAIDs for the treatment of ankylosing spondylitis (AS). 4 Compared to placebo, there was high quality evidence of a significant reduction in pain using the VAS with NSAIDs. Pain in the control group ranged from 57 to 64 on the 100 mm VAS and was 16.5 points lower in the NSAID group (95% CI 12.2 to 20.8). There was moderate quality evidence of improved disease activity with NSAIDs. There was no significant difference in withdrawals due to adverse events (RR 0.75; 95% CI 0.46 to 1.21) or serious adverse events (RR 1.69; 95% CI 0.36 to 7.97). There were no significant differences in pain or harms between NSAID classes. New Guidelines: None identified. New FDA Drug Approvals: None identified.

3 New FDA Safety Alerts: After a recent review of the current safety data, the FDA opted to strengthen the label warning that non aspirin NSAIDs increase the chance of a myocardial infarction and stroke. 5 A review of a meta analysis of RCTs and observational trials were reviewed by the FDA Advisory Committee in Based on this review, the following conclusions were made: 1) a multitude of studies support the finding that NSAIDs can cause serious cardiovascular (CV) thrombotic events (RR 10% 50%) and this risk is also evident in healthy individuals; 2) there could be a significant risk within days to weeks of initiation and there may be a higher risk with longer NSAID use; 3) some observational data suggests that naproxen may have a lower CV risk compared to other NSAIDs. However, this is based on limited data from studies not designed to compare safety between NSAIDs. The ongoing randomized safety trial comparing CV events with celecoxib, naproxen and ibuprofen among high CV risk patients will help determine if there are differences between individual agents; and 4) there is an approximately 2 fold increase in hospitalizations due to heart failure with use of both COX 2 selective and nonselective NSAIDs. References: 1. Jones P, Dalziel SR, Lamdin R, Miles Chan JL, Frampton C. Oral non steroidal anti inflammatory drugs versus other oral analgesic agents for acute soft tissue injury. In: Cochrane Database of Systematic Reviews. John Wiley & Sons, Ltd; Accessed February 10, Enthoven WT, Roelofs PD, Deyo RA, van Tulder MW, Koes BW. Non steroidal anti inflammatory drugs for chronic low back pain. Cochrane Database Syst Rev. 2016;2:CD doi: / cd Bird SB, Dickson EW. Clinically significant changes in pain along the visual analog scale. Ann Emerg Med. 2001;38(6): doi: /mem Kroon FPB, van der Burg LRA, Ramiro S, et al. Non steroidal anti inflammatory drugs (NSAIDs) for axial spondyloarthritis (ankylosing spondylitis and nonradiographic axial spondyloarthritis). Cochrane Database Syst Rev. 2015;7:CD doi: / cd pub2. 5. US Food and Drug Administration. FDA Drug Safety Communication: FDA strengthens warning that non aspirin nonsteroidal anti inflammatory drugs (NSAIDs) can cause heart attacks or strokes. July Available at Accessed 1/7/ Essex MN, Behar R, O Connell MA, Brown PB. Efficacy and tolerability of celecoxib and naproxen versus placebo in Hispanic patients with knee osteoarthritis. Int J Gen Med. 2014;7: doi: /ijgm.s Huang F, Gu J, Liu Y, et al. Efficacy and safety of celecoxib in chinese patients with ankylosing spondylitis: a 6 week randomized, double blinded study with 6 week open label extension treatment. Curr Ther Res Clin Exp. 2014;76: doi: /j.curtheres

4 Appendix 1: Current Status on Preferred Drug List ROUTE FORMULATION BRAND GENERIC PDL ORAL TABLET DICLOFENAC POTASSIUM DICLOFENAC POTASSIUM Y ORAL TABLET DR DICLOFENAC SODIUM DICLOFENAC SODIUM Y ORAL TABLET ETODOLAC ETODOLAC Y ORAL TABLET FLURBIPROFEN FLURBIPROFEN Y ORAL TABLET PROVIL IBUPROFEN Y ORAL CAPSULE ADVIL IBUPROFEN Y ORAL CAPSULE ADVIL LIQUI-GELS IBUPROFEN Y ORAL CAPSULE ADVIL MIGRAINE IBUPROFEN Y ORAL CAPSULE IBUPROFEN IBUPROFEN Y ORAL DROPS SUSP IBU-DROPS IBUPROFEN Y ORAL DROPS SUSP INFANTS IBU-DROPS IBUPROFEN Y ORAL DROPS SUSP INFANTS IBUPROFEN IBUPROFEN Y ORAL DROPS SUSP INFANT'S IBUPROFEN IBUPROFEN Y ORAL DROPS SUSP INFANTS' IBUPROFEN IBUPROFEN Y ORAL ORAL SUSP CHILD IBUPROFEN IBUPROFEN Y ORAL ORAL SUSP CHILDREN'S ADVIL IBUPROFEN Y ORAL ORAL SUSP CHILDREN'S IBUPROFEN IBUPROFEN Y ORAL ORAL SUSP IBUPROFEN IBUPROFEN Y ORAL TAB CHEW ADVIL IBUPROFEN Y ORAL TAB CHEW IBUPROFEN IBUPROFEN Y ORAL TAB CHEW IBUPROFEN IB IBUPROFEN Y ORAL TABLET ADVIL IBUPROFEN Y ORAL TABLET IBUPROFEN IBUPROFEN Y ORAL TABLET IBUPROFEN IB IBUPROFEN Y ORAL CAPSULE INDOMETHACIN INDOMETHACIN Y ORAL CAPSULE KETOPROFEN KETOPROFEN Y ORAL TABLET KETOROLAC TROMETHAMINE KETOROLAC TROMETHAMINE Y ORAL TABLET MELOXICAM MELOXICAM Y ORAL TABLET MOBIC MELOXICAM Y ORAL TABLET NABUMETONE NABUMETONE Y ORAL TABLET ALL DAY PAIN RELIEF NAPROXEN SODIUM Y ORAL TABLET ALL DAY RELIEF NAPROXEN SODIUM Y ORAL TABLET ANAPROX NAPROXEN SODIUM Y ORAL TABLET ANAPROX DS NAPROXEN SODIUM Y ORAL TABLET NAPROSYN NAPROXEN Y ORAL TABLET NAPROXEN NAPROXEN Y

5 ORAL TABLET NAPROXEN SODIUM NAPROXEN SODIUM Y ORAL TABLET DR EC-NAPROSYN NAPROXEN Y ORAL TABLET DR NAPROXEN NAPROXEN Y ORAL TABLET OXAPROZIN OXAPROZIN Y ORAL TABLET DAYPRO OXAPROZIN Y ORAL TABLET SULINDAC SULINDAC Y ORAL CAPSULE CELEBREX CELECOXIB N ORAL CAPSULE CELECOXIB CELECOXIB N ORAL CAPSULE ZIPSOR DICLOFENAC POTASSIUM N ORAL CAPSULE ZORVOLEX DICLOFENAC SUBMICRONIZED N ORAL POWD PACK CAMBIA DICLOFENAC POTASSIUM N ORAL TAB ER 24H DICLOFENAC SODIUM ER DICLOFENAC SODIUM N ORAL TAB IR DR ARTHROTEC 50 DICLOFENAC SODIUM/MISOPROSTOL N ORAL TAB IR DR ARTHROTEC 75 DICLOFENAC SODIUM/MISOPROSTOL N ORAL TAB IR DR DICLOFENAC SODIUM-MISOPROSTOL DICLOFENAC SODIUM/MISOPROSTOL N ORAL TABLET DIFLUNISAL DIFLUNISAL N ORAL CAPSULE ETODOLAC ETODOLAC N ORAL TAB ER 24H ETODOLAC ER ETODOLAC N ORAL TABLET FENOPROFEN CALCIUM FENOPROFEN CALCIUM N ORAL CAPSULE NALFON FENOPROFEN CALCIUM N ORAL TABLET DUEXIS IBUPROFEN/FAMOTIDINE N ORAL CAPSULE ER INDOMETHACIN INDOMETHACIN N ORAL ORAL SUSP INDOCIN INDOMETHACIN N ORAL CAPSULE TIVORBEX INDOMETHACIN, SUBMICRONIZED N ORAL CAP24H PEL KETOPROFEN KETOPROFEN N NASAL SPRAY SPRIX KETOROLAC TROMETHAMINE N ORAL CAPSULE MECLOFENAMATE SODIUM MECLOFENAMATE SODIUM N ORAL CAPSULE MEFENAMIC ACID MEFENAMIC ACID N ORAL CAPSULE PONSTEL MEFENAMIC ACID N ORAL ORAL SUSP MELOXICAM MELOXICAM N ORAL ORAL SUSP MOBIC MELOXICAM N ORAL CAPSULE NAPROXEN SODIUM NAPROXEN SODIUM N ORAL ORAL SUSP NAPROXEN NAPROXEN N ORAL TBMP 24HR NAPRELAN NAPROXEN SODIUM N ORAL TBMP 24HR NAPROXEN SODIUM CR NAPROXEN SODIUM N ORAL TAB IR DR VIMOVO NAPROXEN/ESOMEPRAZOLE MAG N ORAL CAPSULE FELDENE PIROXICAM N ORAL CAPSULE PIROXICAM PIROXICAM N ORAL CAPSULE TOLMETIN SODIUM TOLMETIN SODIUM N ORAL TABLET TOLMETIN SODIUM TOLMETIN SODIUM N

6 Appendix 2: New Clinical Trials A total of 177 citations were manually reviewed from the literature search. After further review, 175 trials were excluded because of wrong study design (observational), comparator (placebo), or outcome studied (non clinical). The remaining 2 trials are briefly described in the table below. Full abstracts are included in Appendix 3. Table 1: Description of Clinical Trials Study Comparison Population Primary Outcome Results Essex, et al. 6 DB, PG, NI, RCT Celecoxib 200 mg daily vs. naproxen 500 mg twice daily(noninferiority study) Hispanics with knee osteoarthritis age 45 years (n=239) Change in patient s assessment of arthritis pain at 6 weeks compared with baseline Reduction in OA Pain (least squares mean change from baseline): Celecoxib: 39.7 mm Naproxen: 36.9 mm P=NS (noninferior) Huang, et al. 7 DB, PG, et al. Celecoxib 200 mg 400 mg daily vs. diclofenac 75 mg daily Chinese subjects with ankylosing spondylitis (n=240) Noninferiority of celecoxib compared with diclofenac in global assessment of pain using the VAS Also no statistically significant differences in GI tolerability, and patient s and physician s global assessments of arthritis Change from baseline in VAS pain scale Celecoxib: 23.8 mm Diclofenac: 27.1 mm Treatment difference: 3.3 mm (95% CI 2.2 to 8.8) Abbreviations: DB = double blind; NI = non inferiority study; OA = osteoarthritis; PG = parallel group; NS = not statistically significant; RCT = randomized controlled trial; VAS = visual analog scale.

7 Appendix 3: Abstracts of Clinical Trials 1. Essex, et al. Efficacy and Tolerability of celecoxib and naproxen versus placebo in Hispanic patients with knee osteoarthritis. Int J Gen Med May 16:7; BACKGROUND: Celecoxib is an effective treatment for osteoarthritis (OA). However, information on its efficacy and safety profile in different racial/ethnic groups is limited. Noticeable differences among racial groups are found in other disease states, but a thorough investigation of OA is lacking. The objective of this study was to determine if celecoxib 200 mg once daily is as effective as naproxen 500 mg twice daily in the treatment of OA of the knee in Hispanic patients. METHODS: Hispanic patients aged 45 years with knee OA were randomized to receive celecoxib 200 mg once daily, naproxen 500 mg twice daily, or placebo for 6 weeks. The primary efficacy variable was the change in Patient's Assessment of Arthritis Pain at 6 weeks compared with baseline. Secondary variables were change in Patient's and Physician's Global Assessments of Arthritis from baseline to week 6/early termination, change in Western Ontario and McMaster Universities OA Index (WOMAC) from baseline to week 6/early termination, change in American Pain Society pain score, Pain Satisfaction Scale, Patient Health Questionnaire (PHQ 9), and measurements of upper gastrointestinal tolerability. RESULTS: In total, 239 patients completed the trial (96 celecoxib, 96 naproxen, 47 placebo). Celecoxib was as effective as naproxen in reducing OA pain (least squares mean change from baseline [standard error] 39.7 [2.7] for celecoxib and 36.9 [2.6] for naproxen). Patient's and Physician's Global Assessments of Arthritis, WOMAC scores, upper gastrointestinal tolerability, Pain Satisfaction Scale, and PHQ 9 showed no statistically significant differences between the celecoxib and naproxen groups. The incidence of adverse events and treatment related adverse events were similar among the treatment groups. CONCLUSION: Celecoxib 200 mg once daily was as effective as naproxen 500 mg twice daily in the treatment of signs and symptoms of knee OA in Hispanic patients. Celecoxib was shown to be safe and well tolerated in this patient population. 2. Huang, et al. Efficacy and Safety of celecoxib in chinese patients with ankylosing spondylitis: a 6 week randomized, double blinded study with 6 week openlabel extension treatment. Curr Ther Res Clin Exp Dec 5:76: BACKGROUND: Nonsteroidal anti inflammatory drugs are the first line option for treating ankylosing spondylitis (AS) in China. However, no large scale controlled trials have been conducted in this ethnic population. OBJECTIVE: To evaluate the efficacy and safety of 6 weeks' treatment with celecoxib in patients with AS in China. METHODS: This Phase 3, double blind, parallel group study randomized patients with AS aged 18 to 65 years 1:1 to receive celecoxib 200 mg once daily or diclofenac sustained release 75 mg once daily. After 6 weeks, patients could use celecoxib 400 mg once daily or maintain blinded therapy. The primary efficacy end point was mean change from baseline at Week 6 for Patient's Global Assessment of Pain Intensity score (100 mm visual analog scale). Noninferiority was established if the upper bound of the CI was <10 mm. Secondary objectives included patients' and physicians' assessments of disease activity, change from baseline in C reactive protein level, and safety.

8 RESULTS: In the per protocol analysis set the least squares mean change from baseline in the Patient's Global Assessment of Pain Intensity score at Week 6 was 23.8 mm and 27.1 mm in patients receiving celecoxib (n = 111) and diclofenac (n = 108), respectively. The 2 sided 95% CI for the treatment difference (celecoxib diclofenac) was 2.2 to 8.8. Overall, 4.2% and 6.7% of patients in the celecoxib and diclofenac groups, respectively, reported treatment related adverse events. All were mild to moderate in severity. CONCLUSIONS: Celecoxib 200 mg once daily is noninferior to diclofenac sustained release 75 mg once daily for pain treatment in Chinese patients with AS. ClinicalTrials.gov identifier: NCT Appendix 4: Medline Search Strategy 1 NSAID.mp or Anti inflammatory agents, non steroidal/ ibuprofen.mp or ibuprofen/ naproxen.mp celecoxib.mp indomethacin/ Ketolrac or ketorolac.mp Nabumetone.mp diclofenac.mp etodolac meloxicam.mp piroxicam.mp Tolmentin.mp or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or limit 13 to (English language and yr=2015 Current clinical trial, all or clinical trial or comparative study or controlled clinical trial or meta analysis or practice guideline or pragmatic clinical trial or randomized controlled trial or systematic reviews) 177

9 Appendix 5: Prior Authorization Criteria Analgesics, Non-Steroidal Anti-Inflammatory Drugs Goal(s): To ensure that non-preferred NSAIDs are used for conditions funded by the OHP. Restrict ketorolac to short-term use (5-day supply every 60 days) per the FDA black boxed warning. Length of Authorization: Up to 12 months Requires PA: Non-preferred NSAIDs. Ketorolac: Maximum of one claim per 60 days, with a maximum 20 tablets/5-day supply (maximum 5-day supply every 60 days). Preferred Alternatives: Preferred alternatives listed at Approval Criteria 1. What diagnosis is being treated? Record ICD10 code. 2. Is the diagnosis funded by the Oregon Health Plan? Yes: Go to #3 No: Pass to RPh; Deny (not funded by the OHP) 3. Is this a continuation of current therapy (i.e. filled prescription within prior 90 days)? Verify via pharmacy claims. 4. Is request for more than a 5-day supply of ketorolac within 60 days (200 mg total over 5 days for tablets, 630 mg total over 5 days for the nasal spray)? Yes: Document prior therapy in PA record. Go to #4. Yes: Pass to RPh. Deny for medical appropriateness. No: Go to #5 No: Go to #5

10 Approval Criteria 5. Will the prescriber consider switching to a preferred product? Message: Preferred products do not require PA or copay. Preferred products are evidence-based reviewed for comparative effectiveness & safety by the Pharmacy and Therapeutics (P&T) Committee. Yes: Inform prescriber of covered alternatives in class. No: Approve for up to 12 months. P&T / DUR Review: 3/16 (MH); 11/14; 9/13; 2/12; 9/09; 2/06 Implementation: 10/15, 1/1/15, 1/1/14, 5/14/12, 1/1/10

Month/Year of Review: January 2012 Date of Last Review: February 2007

Month/Year of Review: January 2012 Date of Last Review: February 2007 Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35, Salem, Oregon 97301-1079 Phone 503-945-5220 Fax 503-947-1119 Month/Year of Review: January 2012 Date of Last Review:

More information

FDA strengthens warning that non-aspirin nonsteroidal antiinflammatory drugs (NSAIDs) can cause heart attacks or strokes

FDA strengthens warning that non-aspirin nonsteroidal antiinflammatory drugs (NSAIDs) can cause heart attacks or strokes FDA strengthens warning that non-aspirin nonsteroidal antiinflammatory drugs (NSAIDs) can cause heart attacks or strokes Safety Announcement [7-9-2015] The U.S. Food and Drug Administration (FDA) is strengthening

More information

Drug Class Review Nonsteroidal Antiinflammatory Drugs (NSAIDs)

Drug Class Review Nonsteroidal Antiinflammatory Drugs (NSAIDs) Drug Class Review Nonsteroidal Antiinflammatory Drugs (NSAIDs) Final Update 4 Report November 2010 The purpose of the is to summarize key information contained in the Drug Effectiveness Review Project

More information

Literature Scan: Alzheimer s Drugs

Literature Scan: Alzheimer s Drugs Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119

More information

Literature Scan: Phosphate Binders

Literature Scan: Phosphate Binders Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119

More information

Literature Scan: Topical Analgesics

Literature Scan: Topical Analgesics Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119

More information

I. Mechanisms of action the role of prostaglandins a. Mediators of inflammation b. and much more

I. Mechanisms of action the role of prostaglandins a. Mediators of inflammation b. and much more NSAID steroid update Leo Semes, OD, FAAO I. Mechanisms of action the role of prostaglandins a. Mediators of inflammation b. and much more II. Topical NSAIDS ophthalmic application III. Oral NSAIDs a. Precautions

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: potassium (Zipsor), (Zorvolex) Reference Number: CP.CPA.280 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Commercial Revision Log See Important Reminder at the end

More information

Drug Class Review Nonsteroidal Antiinflammatory Drugs (NSAIDs)

Drug Class Review Nonsteroidal Antiinflammatory Drugs (NSAIDs) Drug Class Review Nonsteroidal Antiinflammatory Drugs (NSAIDs) Preliminary Scan Report #2 May 2014 Last Report: Update #4 (November 2010) Last Preliminary Scan: July 2013 The purpose of reports is to make

More information

Literature Scan: Analgesics for Gout. Month/Year of Review: April 2015 Date of Last Review: January 2014

Literature Scan: Analgesics for Gout. Month/Year of Review: April 2015 Date of Last Review: January 2014 Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35, Salem, Oregon 97301 1079 Phone 503 947 5220 Fax 503 947 1119 Copyright 2012 Oregon State University. All Rights

More information

Drug Class Review on Cyclo-oxygenase (COX)-2 Inhibitors and Non-steroidal Anti-inflammatory Drugs (NSAIDs)

Drug Class Review on Cyclo-oxygenase (COX)-2 Inhibitors and Non-steroidal Anti-inflammatory Drugs (NSAIDs) Drug Class Review on Cyclo-oxygenase (COX)-2 Inhibitors and Non-steroidal Anti-inflammatory Drugs (NSAIDs) Final Report Update 3 Evidence Tables November 2006 Original Report Date: May 2002 Update 1 Report

More information

Drug Class Literature Scan: Pancreatic Enzymes

Drug Class Literature Scan: Pancreatic Enzymes Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119

More information

Literature Scan: Erythropoiesis Stimulating Agents

Literature Scan: Erythropoiesis Stimulating Agents Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: (Duexis) Reference Number: CP.PMN.120 Effective Date: 06.01.18 Last Review Date: 05.18 Line of Business: Commercial, Medicaid Revision Log See Important Reminder at the end of this policy

More information

Drug Class Review Nonsteroidal Antiinflammatory Drugs (NSAIDs)

Drug Class Review Nonsteroidal Antiinflammatory Drugs (NSAIDs) Drug Class Review Nonsteroidal Antiinflammatory Drugs (NSAIDs) Final Update 4 Report November 2010 The purpose of reports is to make available information regarding the comparative clinical effectiveness

More information

Drug Class Literature Scan: Topical Antipsoriatics

Drug Class Literature Scan: Topical Antipsoriatics Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119

More information

2018 WPS MedicareRx Plan (PDP) Step Therapy

2018 WPS MedicareRx Plan (PDP) Step Therapy 2018 WPS MedicareRx Plan (PDP) Step Therapy In some cases, the WPS MedicareRx Plan (PDP) requires you to first try certain drugs to treat your medical condition before we will cover another drug for that

More information

Literature Scan: Parenteral Antipsychotics

Literature Scan: Parenteral Antipsychotics Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119

More information

NSAID all (Warner-Schmidt) includes all (NSAIDs, Salicytes, and Cox-2 inhibitors)

NSAID all (Warner-Schmidt) includes all (NSAIDs, Salicytes, and Cox-2 inhibitors) Table S1. Medications categorized as s all (Warner-Schmidt) includes all (s, Salicytes, and Cox-2 inhibitors) Nonsteroidal anti-inflammatory agents Bromfenac Diclofenac Diclofenac-misoprostol Etodolac

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: (Celebrex) Reference Number: CP.CPA.239 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Medicaid Medi-Cal Revision Log See Important Reminder at the end of this policy

More information

Information for Vermont Prescribers of Prescription Drugs

Information for Vermont Prescribers of Prescription Drugs Information for Vermont Prescribers of Prescription Drugs ARTHROTEC (diclofenac sodium/misoprostol) tablets This list does not imply that the products on this chart are interchangeable or have the same

More information

Information for Vermont Prescribers of Prescription Drugs

Information for Vermont Prescribers of Prescription Drugs Information for Vermont Prescribers of Prescription Drugs ARTHROTEC (diclofenac sodium/misoprostol) tablets This list does not imply that the products on this chart are interchangeable or have the same

More information

Literature Scan: Drugs for BPH

Literature Scan: Drugs for BPH Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119

More information

COLCRYS-PST. Products Affected Step 1: Mitigare 0.6 mg capsule. Details. Step 2: Colcrys 0.6 mg tablet

COLCRYS-PST. Products Affected Step 1: Mitigare 0.6 mg capsule. Details. Step 2: Colcrys 0.6 mg tablet COLCRYS-PST Mitigare 0.6 mg capsule Colcrys 0.6 mg tablet Criteria If the patient has tried one Step 1 product, authorization for a Step 2 product may be given. Exceptions can be made for a step 2 drug

More information

NSAIDs. NSAIDs are important but they can have side effects.

NSAIDs. NSAIDs are important but they can have side effects. NSAIDs Pain Treatment Nonsteroidal anti-inflammatory drugs (NSAIDs) are often recommended for initial treatment of pain and can be added to more powerful drugs to treat worse pain. Acetaminophen, such

More information

COLCRYS-PST. Products Affected Step 1: Mitigare 0.6 mg capsule. Details. Step 2: Colcrys 0.6 mg tablet

COLCRYS-PST. Products Affected Step 1: Mitigare 0.6 mg capsule. Details. Step 2: Colcrys 0.6 mg tablet COLCRYS-PST Mitigare 0.6 mg capsule Colcrys 0.6 mg tablet Criteria If the patient has tried one Step 1 product, authorization for a Step 2 product may be given. Exceptions can be made for a step 2 drug

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: (Celebrex) Reference Number: CP.PMN.122 Effective Date: 01.01.07 Last Review Date: 05.18 Line of Business: Commercial, HIM, Medicaid Revision Log See Important Reminder at the end of this

More information

These programs and quantity limitations may not apply. Check your certificate or other plan information for benefit details.

These programs and quantity limitations may not apply. Check your certificate or other plan information for benefit details. FlexRx Standard Utilization Management (PA, QL,) Updates January 1, 2018 How to use this drug list This drug list includes updates to Utilization Management (UM) programs. UM may include a prior authorization

More information

Effective Health Care Program

Effective Health Care Program Comparative Effectiveness Review Number 38 Effective Health Care Program Analgesics for Osteoarthritis: An Update of the 2006 Comparative Effectiveness Review Executive Summary Background Osteoarthritis

More information

Non-steroidal Anti-Inflammatory Drugs (Oral/Rectal)

Non-steroidal Anti-Inflammatory Drugs (Oral/Rectal) About Information on indications for use or diagnosis is assumed to be unavailable. All criteria may be applied retrospectively; prospective application is indicated with an asterisk [*]. The information

More information

Literature Scan: Antivirals for Herpes Simplex Virus

Literature Scan: Antivirals for Herpes Simplex Virus Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119

More information

Month/Year of Review: November 2014 Date of Last Review: June 2012 PDL Classes: Anti-anginals, Cardiovascular

Month/Year of Review: November 2014 Date of Last Review: June 2012 PDL Classes: Anti-anginals, Cardiovascular Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35, Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119 Copyright 2012 Oregon State University. All Rights

More information

Clinical Policy: Toremifene (Fareston) Reference Number: CP.PMN.126 Effective Date: Last Review Date: Line of Business: Medicaid

Clinical Policy: Toremifene (Fareston) Reference Number: CP.PMN.126 Effective Date: Last Review Date: Line of Business: Medicaid Clinical Policy: (Fareston) Reference Number: CP.PMN.126 Effective Date: 04.01.10 Last Review Date: 05.18 Line of Business: Medicaid Revision Log See Important Reminder at the end of this policy for important

More information

ALZHEIMER'S DRUGS. Details. Step 2: Exelon Patch 13.3 mg/24 hour transdermal Exelon Patch 4.6 mg/24 hr transdermal

ALZHEIMER'S DRUGS. Details. Step 2: Exelon Patch 13.3 mg/24 hour transdermal Exelon Patch 4.6 mg/24 hr transdermal ALZHEIMER'S DRUGS Products Affected Step 1: donepezil 10 mg disintegrating tablet donepezil 10 mg tablet donepezil 23 mg tablet donepezil 5 mg disintegrating tablet donepezil 5 mg tablet galantamine 12

More information

in people who have heart disease

in people who have heart disease Medication Guide DUEXIS (due ex is) (ibuprofen and famotidine) tablets Read this Medication Guide before you start taking DUEXIS and each time you get a refill. There may be new information. This information

More information

Etodolac versus meloxicam

Etodolac versus meloxicam Etodolac versus meloxicam The Borg System is 100 % Etodolac versus meloxicam Etodolac versus meloxicam -- 722 75051 1991 Wainwright Not Specific Enough. The store also now says majority of Irish willing

More information

The first stop for professional medicines advice. Community Pharmacy NSAID Gastro-Intestinal Safety Audit

The first stop for professional medicines advice. Community Pharmacy NSAID Gastro-Intestinal Safety Audit Community Pharmacy NSAID Gastro-Intestinal Safety Audit Working with Primary Care Commissioning, Strategy and Innovation Directorate The first stop for professional medicines advice www.sps.nhs.uk Community

More information

Texas Prior Authorization Program Clinical Edit Criteria

Texas Prior Authorization Program Clinical Edit Criteria Texas Prior Authorization Program Clinical Edit Criteria Drug/Drug Class Clinical Edit Information Included in this Document Oral Drugs requiring prior authorization: the list of drugs requiring prior

More information

Acetaminophen and NSAIDS. James Moriarity MD University of Notre Dame

Acetaminophen and NSAIDS. James Moriarity MD University of Notre Dame Acetaminophen and NSAIDS James Moriarity MD University of Notre Dame Lecture Goals Understand the indications for acetaminophen and NSAID use in musculoskeletal medicine Understand the role of Eicosanoids

More information

Celecoxib Powder, Diclofenac Powder, Flurbiprofen Powder, Ibuprofen Powder, Ketoprofen Powder, Meloxicam Powder, Tramadol Powder

Celecoxib Powder, Diclofenac Powder, Flurbiprofen Powder, Ibuprofen Powder, Ketoprofen Powder, Meloxicam Powder, Tramadol Powder Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.02.26 Subject: Anti-Inflammatory Pain Powders Page: 1 of 5 Last Review Date: December 3, 2015 Anti-Inflammatory

More information

Available Strengths. Cost per Rx 325 mg tablet - $ mg tablet - $ mg ER tablet - $ mg capsule - $ mg chewable tablet

Available Strengths. Cost per Rx 325 mg tablet - $ mg tablet - $ mg ER tablet - $ mg capsule - $ mg chewable tablet MEDICATION COVERAGE POLICY PHARMACY AND THERAPEUTICS ADVISORY COMMITTEE POLICY Non-Opioids LAST REVIEW 5/9/2017 THERAPEUTIC CLASS Pain REVIEW HISTORY 2/16, 5/15 LOB AFFECTED Medi-Cal (MONTH/YEAR) This

More information

Drug Class Literature Scan: Antianginals

Drug Class Literature Scan: Antianginals Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119

More information

MUSCULOSKELETAL PHARMACOLOGY. A story of the inflamed

MUSCULOSKELETAL PHARMACOLOGY. A story of the inflamed MUSCULOSKELETAL PHARMACOLOGY A story of the inflamed 1 INFLAMMATION Pathophysiology Inflammation Reaction to tissue injury Caused by release of chemical mediators Leads to a vascular response Fluid and

More information

Can i take indomethacin with aspirin

Can i take indomethacin with aspirin Can i take indomethacin with aspirin The Borg System is 100 % Can i take indomethacin with aspirin People who take nonsteroidal anti-inflammatory drugs (NSAIDs) (other than aspirin ) such as indomethacin

More information

Literature Scan: Triptans

Literature Scan: Triptans Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119

More information

Managing Osteoarthritis Pain With Medicines. A Review of the Research for Adults

Managing Osteoarthritis Pain With Medicines. A Review of the Research for Adults Managing Osteoarthritis Pain With Medicines A Review of the Research for Adults Is This Summary Right for Me? Yes, if: A doctor* said you have osteoarthritis (pronounced ah-stee-oharth-rye-tis). Osteoarthritis

More information

Texas Prior Authorization Program Clinical Edit Criteria

Texas Prior Authorization Program Clinical Edit Criteria Texas Prior Authorization Program Clinical Edit Criteria Drug/Drug Class COX-2 Inhibitors Clinical Edit Information Included in this Document COX-2 Inhibitors Celebrex Drugs requiring prior authorization:

More information

Drug Effectiveness Review Project Literature Scan Summary. Month/Year of Review: January 2015 Date of Last Review: January 2013

Drug Effectiveness Review Project Literature Scan Summary. Month/Year of Review: January 2015 Date of Last Review: January 2013 Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35, Salem, Oregon 97301 1079 Phone 503 947 5220 Fax 503 947 1119 Copyright 2012 Oregon State University. All Rights

More information

Common Medications Containing Aspirin and Other Nonsteroidal Anti-inflammatory Drugs (NSAIDs)

Common Medications Containing Aspirin and Other Nonsteroidal Anti-inflammatory Drugs (NSAIDs) PATIENT & CAREGIVER EDUCATION Common Medications Containing Aspirin and Other Nonsteroidal Anti-inflammatory Drugs (NSAIDs) This information will help you identify medications that contain aspirin and

More information

OHSU Drug Effectiveness Review Project Summary Report Long-Acting Insulins

OHSU Drug Effectiveness Review Project Summary Report Long-Acting Insulins Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-2596

More information

Latest Press Release. doubledown casino active chips

Latest Press Release. doubledown casino active chips corp@stantec.com Latest Press Release doubledown casino active chips S Nov 1, 2017. Ibuprofen (Advil, Motrin) and meloxicam (Mobic) are drugs used to manage mild to moderate pain, inflammation, and fever.

More information

Characteristics of selective and non-selective NSAID use in Scotland

Characteristics of selective and non-selective NSAID use in Scotland Characteristics of selective and non-selective NSAID use in Scotland Alford KMG 1, Simpson C 1, Williams D 2 1 Department of General Practice & Primary Care, The University of Aberdeen. 2 Department of

More information

You May Be at Risk. You are currently taking a non-steroidal anti-inflammatory drug (NSAID):

You May Be at Risk. You are currently taking a non-steroidal anti-inflammatory drug (NSAID): NSAIDS You May Be at Risk You are currently taking a non-steroidal anti-inflammatory drug (NSAID): Aspirin Diclofenac (Voltaren ) Diflunisal (Dolobid ) Etodolac (Lodine ) Ibuprofen (Advil ) Ketoprofen

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: ER Injection (Zilretta) Reference Number: CP.PHAR.371 Effective Date: 01.09.18 Last Review Date: 02.18 Line of Business: Commercial, Medicaid Revision Log See Important Reminder at the

More information

Pain therapeutics. Acetaminophen/NSAIDs Acute pain Osteoarthritis Migraine Acute Gout Neuropathic pain

Pain therapeutics. Acetaminophen/NSAIDs Acute pain Osteoarthritis Migraine Acute Gout Neuropathic pain Pain therapeutics Acetaminophen/NSAIDs Acute pain Osteoarthritis Migraine Acute Gout Neuropathic pain James McCormack, Pharm.D. Professor Faculty of Pharmaceutical Sciences, UBC Common types of pain killers

More information

Carmina F. Angeles MD/PhD 74 B Centennial Loop, Suite 100 Eugene, OR Ph (541) Fax (541)

Carmina F. Angeles MD/PhD 74 B Centennial Loop, Suite 100 Eugene, OR Ph (541) Fax (541) Carmina F. Angeles MD/PhD 74 B Centennial Loop, Suite 100 Eugene, OR 97401 Ph (541) 686.3791 Fax (541) 686.3795 DISCHARGE INSTRUCTIONS FOR ANTERIOR CERVICAL DISCECTOMY AND FUSION It is important to me

More information

Literature Scan: Antibiotics for Clostridium difficile Infection. Month/Year of Review: May 2015 Date of Last Review: April 2012

Literature Scan: Antibiotics for Clostridium difficile Infection. Month/Year of Review: May 2015 Date of Last Review: April 2012 Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119

More information

eappendix A. Opioids and Nonsteroidal Anti-Inflammatory Drugs

eappendix A. Opioids and Nonsteroidal Anti-Inflammatory Drugs eappendix A. Opioids and Nonsteroidal Anti-Inflammatory Drugs Nonsteroidal Anti-Inflammatory Drugs Nonselective nonsteroidal anti-inflammatory drugs Diclofenac, etodolac, flurbiprofen, ketorolac, ibuprofen,

More information

**If pre-procedure instructions are not followed, it is likely we will have to cancel or reschedule this injection**

**If pre-procedure instructions are not followed, it is likely we will have to cancel or reschedule this injection** Procedure Date: Procedure Check-in Time: Procedure Start Time: Check In at Diagnostic Imaging on the 2 nd Floor of the Madison Center PRE-PROCEDURE INSTRUCTIONS Please make sure to read over these instructions

More information

2018 STEP THERAPY CRITERIA UCare Connect (SNBC) MinnesotaCare Prepaid Medical Assistance Program (PMAP) Minnesota Senior Care Plus (MSC+)

2018 STEP THERAPY CRITERIA UCare Connect (SNBC) MinnesotaCare Prepaid Medical Assistance Program (PMAP) Minnesota Senior Care Plus (MSC+) 2018 STEP THERAPY CRITERIA UCare Connect (SNBC) MinnesotaCare Prepaid Medical Assistance Program (PMAP) Minnesota Senior Care Plus (MSC+) In some cases, UCare requires you to first try certain drugs to

More information

Month/Year of Review: January 2015 Date of Last Review: January 2010

Month/Year of Review: January 2015 Date of Last Review: January 2010 Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35, Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119 Copyright 2012 Oregon State University. All Rights

More information

Anticholinergics. COMT* Inhibitors. Dopaminergic Agents. Dopamine Agonists. Combination Product

Anticholinergics. COMT* Inhibitors. Dopaminergic Agents. Dopamine Agonists. Combination Product Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35, Salem, Oregon 97301-1079 Phone 503-945-5220 Fax 503-947-1119 Class Update: Parkinson s Drugs Month/Year of Review:

More information

Month/Year of Review: September 2012 Date of Last Review: September 2010

Month/Year of Review: September 2012 Date of Last Review: September 2010 Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35, Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119

More information

Texas Prior Authorization Program Clinical Criteria

Texas Prior Authorization Program Clinical Criteria Texas Prior Authorization Program Clinical Criteria Drug/Drug Class Ketorolac Clinical Criteria Information Included in this Document Ketorolac Oral Drugs requiring prior authorization: the list of drugs

More information

Drug Effectiveness Review Project Summary Report Long acting Insulins

Drug Effectiveness Review Project Summary Report Long acting Insulins Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119

More information

Available Strengths Limits. 10 mg tablet -- $ mg tablet -- $ mg tablet -- $ mg tablet -- $72.41 Avoid use in members over

Available Strengths Limits. 10 mg tablet -- $ mg tablet -- $ mg tablet -- $ mg tablet -- $72.41 Avoid use in members over MEDICATION COVERAGE POLICY PHARMACY AND THERAPEUTICS ADVISORY COMMITTEE POLICY: Fibromyalgia P&T DATE: 5/9/2017 CLASS: Pain Management REVIEW HISTORY 9/15, 5/14, 11/12, 9/12, LOB: Medi-Cal (MONTH/YEAR)

More information

Abbreviated Class Review: Long-Acting Injectable Antipsychotics

Abbreviated Class Review: Long-Acting Injectable Antipsychotics Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35, Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119

More information

Vimovo (delayed-release enteric-coated naproxen with esomeprazole)

Vimovo (delayed-release enteric-coated naproxen with esomeprazole) Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.17.01 Subject: Vimovo Page: 1 of 5 Last Review Date: September 18, 2015 Vimovo Description Vimovo (delayed-release

More information

Literature Scan: Topical Corticosteroids. Month/Year of Review: March 2015 Date of Last Review: March 2013 Source Document: OSU College of Pharmacy

Literature Scan: Topical Corticosteroids. Month/Year of Review: March 2015 Date of Last Review: March 2013 Source Document: OSU College of Pharmacy Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119

More information

COMPOUNDING PHARMACY SOLUTIONS PRESCRIPTION COMPOUNDING FOR PAIN MANAGEMENT

COMPOUNDING PHARMACY SOLUTIONS PRESCRIPTION COMPOUNDING FOR PAIN MANAGEMENT JANUARY 2012 COMPOUNDING PHARMACY SOLUTIONS PRESCRIPTION COMPOUNDING WWW.CPSRXS. COM We customize individual prescriptions for the specific needs of our patients. INSIDE THIS ISSUE: Osteoarthritis Pain

More information

Supplementary appendix: Additional material. Figure S1. Flow-chart of inclusion/exclusion criteria.

Supplementary appendix: Additional material. Figure S1. Flow-chart of inclusion/exclusion criteria. Supplementary appendix: Additional material Figure S1. Flow-chart of inclusion/exclusion criteria. 1 Table S1. Codes considered to identify heart failure patients by the included databases. Coding system

More information

Community Pharmacy NSAID Audit on Gastrointestinal Safety

Community Pharmacy NSAID Audit on Gastrointestinal Safety East & outh East England pecialist Pharmacy ervices East of England, London, outh Central & outh East Coast Medicines Use and afety Community Pharmacy NAID Audit on Gastrointestinal afety Introduction

More information

CARDIOVASCULAR RISK and NSAIDs

CARDIOVASCULAR RISK and NSAIDs CARDIOVASCULAR RISK and NSAIDs Dr. Syed Ghulam Mogni Mowla Assistant Professor of Medicine Shaheed Suhrawardy Medical College, Dhaka INTRODUCTION NSAIDs are most commonly prescribed drugs Recent evidence

More information

2018 STEP THERAPY CRITERIA UCare Connect (SNBC) MinnesotaCare Prepaid Medical Assistance Program (PMAP) Minnesota Senior Care Plus (MSC+)

2018 STEP THERAPY CRITERIA UCare Connect (SNBC) MinnesotaCare Prepaid Medical Assistance Program (PMAP) Minnesota Senior Care Plus (MSC+) 2018 STEP THERAPY CRITERIA UCare Connect (SNBC) MinnesotaCare Prepaid Medical Assistance Program (PMAP) Minnesota Senior Care Plus (MSC+) In some cases, UCare requires you to first try certain drugs to

More information

RxBlue 2010 ST Criteria

RxBlue 2010 ST Criteria RxBlue 2010 ST Criteria ANTIDEPRESSANTS - SARAFEM... 10 FLUOXETINE HCL... 10 SARAFEM... 10 SELFEMRA... 10 ANTIDEPRESSANTS- SSRI, SNRI... 11 CELEXA... 11 CITALOPRAM... 11 CYMBALTA... 11 EFFEXOR XR... 11

More information

Is naproxen the same as ibuprofen

Is naproxen the same as ibuprofen You could but it is not recommended. The same goes for Aleve ( naproxen ). You might try Tylenol instead. Ibuprofen is used primarily to treat fever (including postimmunisation fever), mild to moderate

More information

HAQ-II(Health Assessment Questionnaire-II)

HAQ-II(Health Assessment Questionnaire-II) Kathy Karamlou, MD 355 Placentia Ave, suite 208 Newport Beach, CA 92663 949-631-6500 949-631-9700 NAME: DATE: DOB: HAQ-II(Health Assessment Questionnaire-II) We are interested in learning how your illness

More information

Analgesic Subcommittee of PTAC Meeting held 1 March 2016

Analgesic Subcommittee of PTAC Meeting held 1 March 2016 Analgesic Subcommittee of PTAC Meeting held 1 March 2016 (minutes for web publishing) The Analgesic Subcommittee minutes are published in accordance with the Terms of Reference for the Pharmacology and

More information

Scottish Medicines Consortium

Scottish Medicines Consortium Scottish Medicines Consortium ketoprofen/, 100mg/20mg; 200mg/20mg modified release capsules (Axorid ) No. (606/10) Meda Pharmaceuticals 05 February 2010 The Scottish Medicines Consortium (SMC) has completed

More information

Abbreviated Class Review: Long-Acting Injectable Antipsychotics

Abbreviated Class Review: Long-Acting Injectable Antipsychotics Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35, Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119

More information

Presentation Outline. Introduction to Biomedical Research Designs. EBM: A Practical Definition. Grade the Evidence (Example McMaster Grading System)

Presentation Outline. Introduction to Biomedical Research Designs. EBM: A Practical Definition. Grade the Evidence (Example McMaster Grading System) Presentation Outline Introduction to Biomedical Research Designs Sean D. Sullivan, R.Ph., PhD Professor of Pharmacy, Public Health and Medicine University of Washington Why a course in Biomedical Research

More information

A Statewide Evaluation of Opioid Prescribing Patterns with an Emphasis on Drug Diversion and Substance Abuse

A Statewide Evaluation of Opioid Prescribing Patterns with an Emphasis on Drug Diversion and Substance Abuse A Statewide Evaluation of Opioid Prescribing Patterns with an Emphasis on Drug Diversion and Substance Abuse INVESTIGATIVE TEAM: STEERING COMMITTEE FOR THE TUFTS HEALTH CARE INSTITUTE ON OPIOID RISK MANAGEMENT

More information

Cymbalta anti inflammatory

Cymbalta anti inflammatory Cymbalta anti inflammatory The Borg System is 100 % Cymbalta anti inflammatory 11/01/2017 Abcya math man games 11/02/2017 Lalaloopsy 11/03/2017 Free keno wheels Cymbalta and ibuprofen. View detailed information

More information

PRESCRIBING SUPPORT TEAM AUDIT: Etoricoxib hypertension safety evaluation

PRESCRIBING SUPPORT TEAM AUDIT: Etoricoxib hypertension safety evaluation PRESCRIBING SUPPORT TEAM AUDIT: Etoricoxib hypertension safety evaluation DATE OF AUTHORISATION: AUTHORISING GP: PRESCRIBING SUPPORT TECHNICIAN: SUMMARY This audit has been designed to ensure that patients

More information

Disclosure. Learning Objectives 1/17/2018. Pumping the Breaks in Pain Management: An Update on Cardiovascular Risk with NSAID Use

Disclosure. Learning Objectives 1/17/2018. Pumping the Breaks in Pain Management: An Update on Cardiovascular Risk with NSAID Use Disclosure Pumping the Breaks in Pain Management: An Update on Cardiovascular Risk with Liz Van Dril, PharmD, BCPS PGY2 Ambulatory Care Resident January 17 th, 2018 Dr. Liz Van Dril has no actual or potential

More information

Accel-Celecoxib Product Monograph Page 52 of 56

Accel-Celecoxib Product Monograph Page 52 of 56 PART III: CONSUMER INFORMATION Pr ACCEL-CELECOXIB CAPSULES Read this information each time you refill your prescription in case new information has been added. This leaflet is a summary designed specifically

More information

Database of Abstracts of Reviews of Effects (DARE) Produced by the Centre for Reviews and Dissemination Copyright 2017 University of York.

Database of Abstracts of Reviews of Effects (DARE) Produced by the Centre for Reviews and Dissemination Copyright 2017 University of York. A comparison of the cost-effectiveness of five strategies for the prevention of non-steroidal anti-inflammatory drug-induced gastrointestinal toxicity: a systematic review with economic modelling Brown

More information

Fact Sheet 2. Patient Tool Kit Types of Pain Medications. Chronic pain is pain that lasts longer than it should and serves no useful purpose.

Fact Sheet 2. Patient Tool Kit Types of Pain Medications. Chronic pain is pain that lasts longer than it should and serves no useful purpose. Sheet 2 Fact Sheet 2 Types of Pain Medications Chronic pain is pain that lasts longer than it should and serves no useful purpose. You may have heard the familiar phrase no two people are exactly alike.

More information

PRODUCT MONOGRAPH. naproxen. 375 & 500 mg Enteric-Coated Tablet 750 mg Sustained-Release Tablet

PRODUCT MONOGRAPH. naproxen. 375 & 500 mg Enteric-Coated Tablet 750 mg Sustained-Release Tablet PRODUCT MONOGRAPH Pr NAPROSYN naproxen 375 & 500 mg Enteric-Coated Tablet 750 mg Sustained-Release Tablet Pharmaceutical Standard: Professed (Sustained-Release Tablet), House (Enteric-Coated Tablet) Non-Steroidal

More information

Algorithm for Use of Non-steroidal Anti-inflammatories (NSAIDs)

Algorithm for Use of Non-steroidal Anti-inflammatories (NSAIDs) Algorithm for Use of Non-steroidal Anti-inflammatories (NSAIDs) Page 3 Publisher Conseil du médicament www.cdm.gouv.qc.ca Coordination Anne Fortin, Pharmacist Development Conseil du médicament Fédération

More information

Month/Year of Review: May 2014 Date of Last Review: September New Drug Evaluation: Sucrofferic Oxyhydroxide (Velphoro )

Month/Year of Review: May 2014 Date of Last Review: September New Drug Evaluation: Sucrofferic Oxyhydroxide (Velphoro ) Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35, Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119

More information

Month/Year of Review: September 2012 Date of Last Review: September 2010

Month/Year of Review: September 2012 Date of Last Review: September 2010 Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35, Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119

More information

Month/Year of Review: March 2014 Date of Last Review: April 2012

Month/Year of Review: March 2014 Date of Last Review: April 2012 Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35, Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119 Copyright 2012 Oregon State University. All Rights

More information

Clinical Policy: Hyaluronate Derivatives Reference Number: ERX.SPA.175 Effective Date:

Clinical Policy: Hyaluronate Derivatives Reference Number: ERX.SPA.175 Effective Date: Clinical Policy: Reference Number: ERX.SPA.175 Effective Date: 01.11.17 Last Review Date: 11.17 Revision Log See Important Reminder at the end of this policy for important regulatory and legal information.

More information

New Dosage Formulation. Month/Year of Review: June 2012 End date of literature search: May Dossier Received: No (Requested)

New Dosage Formulation. Month/Year of Review: June 2012 End date of literature search: May Dossier Received: No (Requested) Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35, Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119

More information

Prevention and management of ASA/NSAID hypersensitivity

Prevention and management of ASA/NSAID hypersensitivity WISC 2012 Hydrabad, India PG Course, Dec 6, 2012 Prevention and management of ASA/NSAID hypersensitivity Hae- Sim Park, Professor Department of Allergy & Clinical Immunology Ajou University School of Medicine,

More information

This document has not been circulated to either the industry or Consultants within the Suffolk system.

This document has not been circulated to either the industry or Consultants within the Suffolk system. New Medicine Report Document Status COX II Inhibitors In Acute Analgesia For Suffolk Drug & Therapeutics Committee Date of Last Revision 15 th February 2002 Reviewer s Comments There seems to be a growing

More information

Class Update with New Drug Evaluation: Influenza Antiviral Agents

Class Update with New Drug Evaluation: Influenza Antiviral Agents Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119

More information

Month/Year of Review: January 2012 Date of Last Review: September 2010

Month/Year of Review: January 2012 Date of Last Review: September 2010 Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35, Salem, Oregon 97301-1079 Phone 503-945-5220 Fax 503-947-1119 Month/Year of Review: January 2012 Date of Last Review:

More information